Chronic Myeloid Leukemia Coverage from Every Angle
Advertisement
Advertisement

Recent News

Lymphoid Blast Transformation of CML: Case Study
Long-Term Benefits and Toxicity of Dasatinib in Imatinib-Resistant CML
How Sensitive Is the EUTOS ELTS Score for CML?
Newly Diagnosed CML: Link Between BMI and Outcomes?
Case Report: Leukemia Related to Therapy for Pancreatic Neuroendocrine Tumor
Is Switching TKIs Effective in Achieving Clinical Response in Chronic-Phase CML?
Rare Occurrence of Secondary CML After AML: Case Study
Search for Optimal Dose of Ponatinib for Chronic-Phase CML: Update From OPTIC Trial
Case Report of CML With T315I Mutation: Combination Therapy With Axitinib and Dasatinib
What Factors Contribute to Functional Loss of SETD2 in CML?
Prognostic Factors for Molecular Relapse–Free Survival in CML
SOHO 2020: TKI Discontinuation and Adherence to Practice Guidelines in Chronic-Phase CML
Discontinuing TKI Therapy in CML: Focus on Treatment-Free Remission
SARS-CoV-2 Infection and CML: Case Report of Severe Hematologic Presentation
SOHO 2020: Indian Study of Protective Potential of Imatinib Against Malaria
SOHO 2020: Predicting Treatment-Free Remission With Nilotinib in Chronic-Phase CML
Do Associated Comorbidities Affect Oxidative Stress in CML?
Case Study: Does Hemodialysis Reduce Tyrosine Kinase Inhibitor Concentration in CML?
British Society for Haematology Guideline for Management of CML
Does Time to Response Impact Outcomes in Accelerated-Phase CML?
CML and COVID-19: Treatment Lessons Learned
Imatinib-Treated CML: A Contraindication to Renal Transplantation?
Canadian Study on Treatment Choices and Outcomes for Children With CML
CML AND COVID-19: Case Report of Successful Treatment With Tocilizumab
Medication Adherence and Its Effect on Molecular Response in CML
COVID-19 and CML: Case Report Involving Febrile Neutropenia and ARDS
UK TARGET CML Study: Comparing Real-World TKI Outcomes
Update From BYOND Trial of Bosutinib in Chronic-Phase CML
COVID-19 and CML: Patient Survey Results From China
Renal Toxicity in Patients With CML After Discontinuation of TKIs
EHA25 Virtual: Update on Second-Generation TKIs and Relapse in CML
Prevalence of Late Effects of TKIs in Patients With CML
EHA25 Virtual: Nilotinib Induction Therapy for Chronic Phase CML
EHA25 Virtual: Extended Follow-up on Early Switch From Imatinib to Dasatinib in CML
AACR II: Race-Based Survival Differences in Patients With CML Living in Texas
EHA25 Virtual: Nilotinib in Patients With CML Who Relapse After Discontinuing Imatinib
ASCO20: Are Providers Following Practice Guidelines for Discontinuation of TKIs?
EHA25 Virtual: Dose Reduction of Second-Generation TKIs in CML
EHA25 Virtual: Low-Dose Ponatinib for Patients With CML
Identifying Key Regulating Proteins in CML With CRISPR Technology
ASCO20: Long-Term Study Update on Bosutinib for Imatinib-Resistant CML
ASCO 2020: Early Results of Ponatinib Dose-Range Study in CML
ASCO20: Bosutinib for Patients With TKI-Intolerant CML


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.